<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03780049</url>
  </required_header>
  <id_info>
    <org_study_id>HCC-S032</org_study_id>
    <nct_id>NCT03780049</nct_id>
  </id_info>
  <brief_title>HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B</brief_title>
  <official_title>Hepatic Artery Infusion Chemotherapy Plus Recombinant Human Type-5 Adenovirus vs Hepatic Artery Infusion Chemotherapy Alone for Unresectable Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer A-B Stage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatic artery infusion chemotherapy (HAIC) is effective and safe for hepatocellular
      carcinoma (HCC). Recombinant Human Type-5 Adenovirus (H101) is safe for HCC. The purpose of
      this study is to evaluate the efficacy and safety of HAIC combined with H101 compared with
      HAIC alone in patients with unresectable hepatocellular carcinoma (HCC) at barcelona clinic
      liver cancer A-B stage.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2018</start_date>
  <completion_date type="Anticipated">October 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>OS was defined as the duration from the date of randomization until the date of death from any cause. Participants who were lost to follow-up were censored at the last date the participant was known to be alive, and participants who remained alive were censored at the time of data cutoff.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS was defined as the time from the date of randomization to the date of first documentation of disease progression based on modified Response Evaluation Criteria in Solid Tumors (mRECIST), or date of death, whichever occurred first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Postoperative adverse events were graded based on CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conversion rate to resection</measure>
    <time_frame>24 months</time_frame>
    <description>Patients receive subsequent resection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">304</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>HAIC plus H101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oxaliplatin, 5-fluorouracil and leucovorin and recombinant human type-5 adenovirus 0.5ml via hepatic artery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HAIC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive oxaliplatin, 5-fluorouracil and leucovorin and normal saline via hepatic artery</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>HAIC of FOLFOX</intervention_name>
    <description>administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries</description>
    <arm_group_label>HAIC</arm_group_label>
    <arm_group_label>HAIC plus H101</arm_group_label>
    <other_name>Hepatic artery infusion chemotherapy of oxaliplatin , fluorouracil, and leucovorin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>H101</intervention_name>
    <description>Patients receive H101 0.5ml dissolved in 10ml normal saline in each session of HAIC</description>
    <arm_group_label>HAIC plus H101</arm_group_label>
    <other_name>Recombinant Human Type-5 Adenovirus</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>Patients receive normal saline 10ml in each session of HAIC</description>
    <arm_group_label>HAIC</arm_group_label>
    <other_name>normal saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The diagnosis of HCC

          -  Patients must have at least one tumor lesion that can be accurately measured according
             to mRECIST criteria.

          -  With no previous treatment

          -  Single lesion with tumor size larger 7cm or multiple lesions

          -  No Cirrhosis or cirrhotic status of Child-Pugh class A only

          -  Not amendable to surgical resection ,local ablative therapy and any other cured
             treatment.

          -  BCLC A-B stage

          -  The following laboratory parameters:

        Platelet count ≥ 50,000/μL Hemoglobin ≥ 8.5 g/dL Total bilirubin ≤ 30mmol/L Serum albumin ≥
        32 g/L ASL and AST ≤ 6 x upper limit of normal Serum creatinine ≤ 1.5 x upper limit of
        normal INR ≤ 1.5 or PT/APTT within normal limits Absolute neutrophil count (ANC) &gt;1,500/mm3

        Exclusion Criteria:

          -  Patients complicated by history of heart disease, history of gastrointestinal bleeding
             within 1 month, severe infection (&gt; grade 2 National Cancer Institute [NCI] -common
             Terminology Criteria for Adverse Events [CTCAE] version 4.0) or other serious
             associated diseases will not be able to tolerate treatment

          -  With other malignant tumors

          -  Known or suspected allergy to the investigational agents or any agent given in
             association with this trial

          -  History of organ allograft

          -  Pregnant or lactating woman

          -  patients with poor compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ming Shi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ming Shi, MD</last_name>
    <phone>+862087343938</phone>
    <email>shiming@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cancer Center Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming Shi, MD</last_name>
      <phone>8620-87343115</phone>
      <email>shiming@mail.sysu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 17, 2018</study_first_submitted>
  <study_first_submitted_qc>December 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>May 19, 2020</last_update_submitted>
  <last_update_submitted_qc>May 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Shi Ming</investigator_full_name>
    <investigator_title>Proffessor</investigator_title>
  </responsible_party>
  <keyword>Hepatocellular Carcinoma</keyword>
  <keyword>Hepatic artery infusion chemotherapy</keyword>
  <keyword>Oxaliplatin, 5-fluorouracil and leucovorin</keyword>
  <keyword>Recombinant Human Type-5 Adenovirus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

